EUVIMEDEUVIMED entdecken
Kohortenstudie

The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center

Caroline Dix iD, Andrew J Doyle iD, Karen Breen, Beverley J Hunt

Thrombosis and Haemostasis · 2025-04 · 125 (04) · 379-384

DOI: 10.1055/a-2379-7288 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 21.08.2024. Verfasst von Caroline Dix und 3 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia and Thrombosis Centre, Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Venous Thromboembolism, Antithrombin III Deficiency, Anticoagulants, Antithrombins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with inherited antithrombin deficiency (IATD) have a high risk of venous thromboembolism (VTE). Most VTEs are managed with direct oral anticoagulants (DOACs), but the utility of DOACs in antithrombin deficiency (ATD) is unreported. Patients with IATD treated with DOAC were identified from our institutions' IATD registry. We assessed patients' characteristics, ATD type, and initial VTE characteristics, thrombosis recurrence and bleeding rates. Thirty-three patients received DOACs for 73 (38.5–111.5) months (median (interquartile range)). Prior to taking DOACs, 12 (36%) patients had VTE recurrence: these occurred after anticoagulation was ceased (4), nonadherence to VKA prior to DOAC use (3), or during heparin use in pregnancy (5). There were no VTE recurrences on standard-dose DOAC, except in a noncompliant patient receiving dabigatran. There was one recurrence with compliant DOAC use—a patient receiving rivaroxaban 10 mg. Six (18%) patients experienced clinically relevant bleeding, which was predominantly menorrhagia (5/6). One major bleeding event, intracranial hemorrhage, occurred in a patient receiving full-dose rivaroxaban who had refractory hypertension (0.5 events/100 patient-years). In this cohort, compliant DOAC users had an overall VTE recurrence rate of 0.5/100 patient-years, whereas with low-dose DOACs the event rate was 3.5/100 patient-years. Standard-dose DOACs appear efficacious and relatively safe in IATD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismAntithrombin III DeficiencyAnticoagulantsAntithrombinsFactor Xa InhibitorsHumansFemaleMaleTertiary Care CentersMiddle AgedAdultHemorrhageRecurrenceTreatment OutcomeRegistriesAdministration, OralAgedRivaroxabanRisk FactorsCohort StudiesPregnancyRetrospective StudiesDabigatran

Substanzen

AnticoagulantsAntithrombinsRivaroxabanFactor Xa InhibitorsDabigatran

Autor:innen und Institutionen

  • Haemophilia and Thrombosis Centre, Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom.

ORCID-Profile: Caroline Dix, Andrew J Doyle

Zitieren

APA

Dix, C., Doyle, A. J., Breen, K., & Hunt, B. J. (2025). The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center. Thrombosis and Haemostasis, 125(04), 379-384. https://doi.org/10.1055/a-2379-7288

Vancouver

Dix C, Doyle AJ, Breen K, Hunt BJ. The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center. Thrombosis and Haemostasis. 2025;125(04):379-384. doi:10.1055/a-2379-7288

BibTeX
@article{Dix2025,
  author = {Dix, Caroline and Doyle, Andrew J and Breen, Karen and Hunt, Beverley J},
  title = {The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {04},
  pages = {379--384},
  doi = {10.1055/a-2379-7288}
}
Kostenlos starten →